Screening for Atrial Fibrillation

Author:

Freedman Ben1,Camm John1,Calkins Hugh1,Healey Jeffrey S.1,Rosenqvist Mårten1,Wang Jiguang1,Albert Christine M.1,Anderson Craig S.1,Antoniou Sotiris1,Benjamin Emelia J.1,Boriani Giuseppe1,Brachmann Johannes1,Brandes Axel1,Chao Tze-Fan1,Conen David1,Engdahl Johan1,Fauchier Laurent1,Fitzmaurice David A.1,Friberg Leif1,Gersh Bernard J.1,Gladstone David J.1,Glotzer Taya V.1,Gwynne Kylie1,Hankey Graeme J.1,Harbison Joseph1,Hillis Graham S.1,Hills Mellanie T.1,Kamel Hooman1,Kirchhof Paulus1,Kowey Peter R.1,Krieger Derk1,Lee Vivian W. Y.1,Levin Lars-Åke1,Lip Gregory Y. H.1,Lobban Trudie1,Lowres Nicole1,Mairesse Georges H.1,Martinez Carlos1,Neubeck Lis1,Orchard Jessica1,Piccini Jonathan P.1,Poppe Katrina1,Potpara Tatjana S.1,Puererfellner Helmut1,Rienstra Michiel1,Sandhu Roopinder K.1,Schnabel Renate B.1,Siu Chung-Wah1,Steinhubl Steven1,Svendsen Jesper H.1,Svennberg Emma1,Themistoclakis Sakis1,Tieleman Robert G.1,Turakhia Mintu P.1,Tveit Arnljot1,Uittenbogaart Steven B.1,Van Gelder Isabelle C.1,Verma Atul1,Wachter Rolf1,Yan Bryan P.1,Al Awwad A,Al-Kalili F,Berge T,Breithardt G,Bury G,Caorsi WR,Chan NY,Chen SA,Christophersen I,Connolly S,Crijns H,Davis S,Dixen U,Doughty R,Du X,Ezekowitz M,Fay M,Frykman V,Geanta M,Gray H,Grubb N,Guerra A,Halcox J,Hatala R,Heidbuchel H,Jackson R,Johnson L,Kaab S,Keane K,Kim YH,Kollios G,Løchen ML,Ma C,Mant J,Martinek M,Marzona I,Matsumoto K,McManus D,Moran P,Naik N,Ngarmukos T,Prabhakaran D,Reidpath D,Ribeiro A,Rudd A,Savalieva I,Schilling R,Sinner M,Stewart S,Suwanwela N,Takahashi N,Topol E,Ushiyama S,Verbiest van Gurp N,Walker N,Wijeratne T

Affiliation:

1. From Heart Research Institute, Charles Perkins Centre, and Concord Hospital Cardiology, University of Sydney, Australia (B.F.); St Georges Hospital, London, UK (J.C.); Johns Hopkins University, Baltimore, MD (H.C.); Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada (J.S.H., D.C.); Karolinska Institute, Stockholm, Sweden (M.R., J.E., L.F., E.S.); The Shanghai Institute of Hypertension, Ruijin Hospital, Jiaotong University School of Medicine, China (J.W.); Brigham...

Abstract

Approximately 10% of ischemic strokes are associated with atrial fibrillation (AF) first diagnosed at the time of stroke. Detecting asymptomatic AF would provide an opportunity to prevent these strokes by instituting appropriate anticoagulation. The AF-SCREEN international collaboration was formed in September 2015 to promote discussion and research about AF screening as a strategy to reduce stroke and death and to provide advocacy for implementation of country-specific AF screening programs. During 2016, 60 expert members of AF-SCREEN, including physicians, nurses, allied health professionals, health economists, and patient advocates, were invited to prepare sections of a draft document. In August 2016, 51 members met in Rome to discuss the draft document and consider the key points arising from it using a Delphi process. These key points emphasize that screen-detected AF found at a single timepoint or by intermittent ECG recordings over 2 weeks is not a benign condition and, with additional stroke factors, carries sufficient risk of stroke to justify consideration of anticoagulation. With regard to the methods of mass screening, handheld ECG devices have the advantage of providing a verifiable ECG trace that guidelines require for AF diagnosis and would therefore be preferred as screening tools. Certain patient groups, such as those with recent embolic stroke of uncertain source (ESUS), require more intensive monitoring for AF. Settings for screening include various venues in both the community and the clinic, but they must be linked to a pathway for appropriate diagnosis and management for screening to be effective. It is recognized that health resources vary widely between countries and health systems, so the setting for AF screening should be both country- and health system-specific. Based on current knowledge, this white paper provides a strong case for AF screening now while recognizing that large randomized outcomes studies would be helpful to strengthen the evidence base.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3